# A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

> **NCT04951609** · PHASE1 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 31 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Seltorexant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04951609
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-02
- **Primary completion:** 2024-04-08
- **Final completion:** 2024-04-08
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Following discussion on pediatric strategy with HAs, it was determined that we have sufficient data to inform next steps for the seltorexant pediatric program.
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04951609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04951609, "A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04951609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*